Amarin Corporation (AMRN) Q2 2025 earnings summary

Executive summary

• Entered a long-term licensing and supply agreement with Recordati to accelerate Vascepa/VAZKEPA commercialization in 59 European countries, shifting the core franchise to a partner with strong cardiovascular expertise and infrastructure.

• Implemented a global restructuring plan following the Recordati agreement, targeting $70 million in annualized operating expense savings, with $22.8 million in charges recognized in Q2 2025, mainly from European workforce reductions.

• Q2 2025 saw solid product sales growth in Europe and other key markets, while U.S. business remained foundational but faced a 17% sales decline and stable market share at 43%.

• Vascepa/VAZKEPA is now approved in 50 countries, with growing support from medical societies and key opinion leaders worldwide.

• Ended Q2 2025 with a strong cash position of $298.7 million and no debt, supporting future growth initiatives.

Financial highlights

• Q2 2025 total net revenue was $72.7 million, up 8% year-over-year, primarily due to a $25 million upfront payment from the Recordati deal and international growth.

• Q2 2025 net product revenue was $46.6 million, down 2% year-over-year, with U.S. revenue declining 17% and European revenue rising 85%.

• Q2 2025 licensing and royalty revenue was $26.1 million, up 31% year-over-year, reflecting the Recordati agreement.

• Gross margin improved to 52% in Q2 2025 from 48% in Q2 2024, due to a favorable customer mix.

• Reported net loss of $14.1 million for Q2 2025, compared to net income of $1.5 million in Q2 2024, primarily due to the restructuring charge.

Outlook and guidance

• Expect to maintain U.S. exclusive payer positions through 2025, with further clarity on 2026 later in the year.

• Prepared to launch an authorized generic in the U.S. when market conditions are optimal.

• Anticipate $70 million in annualized cost savings from restructuring, to be realized on a straight-line basis over the next four quarters.

• Focused on supporting Recordati's commercialization efforts in Europe, expanding global partnerships, and maximizing shareholder value.

• Expects to slow cash decline and is on an accelerated path to achieving positive free cash flow.